Phase 3 Trial Finds Benlysta Significantly Improves Kidney Response in People with Lupus Nephritis
UPDATE 16/09/2020
In new results on the international phase 3 clinical trial (BLISS-LN) of the drug Benlysta (belimumab), researchers found that Benlysta reduced the risk of worsening kidney function during the study by almost 50%, compared with standard therapy alone.
The groundbreaking results from the phase 3 BLISS-LN clinical trial could lead to Benlysta becoming the first drug approved by the Food and Drug Administration (FDA) (United States of America) to treat lupus nephritis, the most common severe complication of SLE that could lead to end-stage kidney disease and death.
